20:15 , Mar 24, 2017 |  BC Week In Review  |  Clinical News

Triheptanoin: Ph II data

Top-line data from a double-blind, international Phase II trial in 36 patients with seizures associated with glucose transporter type-1 deficiency syndrome showed that oral triheptanoin given 4 times daily missed the primary endpoint of reducing...
21:06 , Feb 3, 2017 |  BC Week In Review  |  Company News

Pro Bono Bio, Spero deal

Spero acquired multiple antibacterial candidates from Pro Bono Bio. Spero said it will work with Pro Bono Bio’s Cantab Anti Infectives Ltd. company to co-develop the compounds to treat multidrug-resistant strains of Gram-negative pathogens, such...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

Triheptanoin: Phase II started

Ultragenyx began a double-blind, placebo-controlled, international Phase II trial to evaluate oral triheptanoin given 4 times daily in up to 50 patients ages 3-17 years with glucose transporter type-1 deficiency syndrome who are not on...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

Metadoxine: Phase IIb data

A double-blind, crossover, Israeli Phase IIb trial in 36 adults with predominantly inattentive ADHD showed that a single dose of 1,400 mg MG01CI met the primary endpoint of improving mean TOVA ADHD scores from baseline...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

Metadoxine: Completed Phase II enrollment

Alcobra completed enrollment of 36 patients with predominantly inattentive ADHD in a double-blind, crossover, Israeli Phase II trial evaluating placebo and once-daily 700 and 1,400 mg oral MG01CI each for 1 week. The trial comprises...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

MG01CI: Phase II started

Alcobra began a placebo-controlled, crossover, Israeli Phase II trial to evaluate 700 and 1,400 mg oral MG01CI once daily for a week in up to 36 adult patients with predominantly inattentive ADHD. The trial comprises...
07:00 , Mar 18, 2013 |  BC Week In Review  |  Company News

Cantab Biopharmaceuticals, PolyTherics deal

PolyTherics said it received an undisclosed milestone payment from the Cantab subsidiary of Celtic Pharma Holdings Advisors LLP. PolyTherics said the milestone was triggered by further progress on a 2010 hematology deal with Cantab to...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Company News

Medical Research Council pharmaceuticals news

The U.K.'s three-year, £180 million ($285.8 million) Biomedical Catalyst fund awarded £39 million ($62.4 million) across 10 universities and 22 small and medium sized enterprises (SMEs) for early stage life science research. Companies receiving funding...
07:00 , Mar 29, 2010 |  BC Week In Review  |  Company News

Antitope, Cantab Biopharmaceuticals deal

Antitope will generate a high-yielding manufacturing mammalian cell line to develop a "biosuperior" protein therapeutic for a hematologic indication for Cantab. Further terms were not disclosed. Antitope Ltd. , Cambridge, U.K.   Cantab Biopharmaceuticals Ltd....
08:00 , Feb 1, 2010 |  BC Week In Review  |  Company News

Cantab Biopharmaceuticals management update

Cantab Biopharmaceuticals Ltd. , Cambridge, U.K.   Business: Biosimilars   Hired: Jim Mills as CEO, formerly director of operations at Cambridge Biomanufacturing Ltd.  ...